Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Items 401–500 of 660
Добрынина, Л. А., Tsypushtanova, M. M., Шабалина, А. А., Витальевна, Ш. К., Геннадьевна, М. А., Trubitsyna, V. V., Bitsieva, E. T., Byrochkina, A. A., & Geints, A. A. (2023) · Annals of Clinical and Experimental Neurology · doi:10.54101/acen.2023.3.3 · Cited by 3
Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort
Gleerup, H. S., Simonsen, A. H., Grötschel, L., Gramkow, M. H., Høgh, P., Blennow, K., Zetterberg, H., Ashton, N. J., & Hasselbalch, S. G. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70073 · Cited by 3
Self-citationPrevalencia del Alzheimer en adultos mayores de América Latina. Revisión bibliográfica
Núñez Valencia, V. A., & Perugachi, J. D. C. N. (2025) · Ciencia y Educación · doi:10.5281/zenodo.14948083 · Cited by 3
Rizvi, B. M., Adams, J. N., Bamford, A. R., Kim, S., Sathishkumar, M. T., Tustison, N. J., Taylor, L., Tuteja, N., McMillan, L. C., Nan, B., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70415 · Cited by 3
Morrison, L., Dyer, A. H., Dolphin, H., Batten, I., Reddy, C., Widdowson, M., Woods, C. P., Gibney, J., Bourke, N. M., & Kennelly, S. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100862 · Cited by 3
Meyer, S. D., Alali, S., Laroy, M., Casteele, T. V., Cauwenberge, M. G. A. V., Goossens, J., Rocker, C. D., Vanbrabant, J., Vanmechelen, E., den Stock, J. V., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf207 · Cited by 3
Maschio, C., Wang, J., Maheshwari, U., Keller, A., Rominger, A., Konietzko, U., Nordberg, A. K., Höck, C., Nitsch, R. M., & Ni, R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582443 · Cited by 3
Pa, C., Shen, S., Dai, Y. L., & Wu, M. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1614132 · Cited by 2
Blood will tell: plasma biomarkers in isolated REM sleep behavior disorder
Ibrahim, A., Süzgün, M. A., & Stefani, A. (2025) · SLEEP · doi:10.1093/sleep/zsaf191 · Cited by 2
Jiang, D., Yue, A., Nan, H., Hou, J., Chu, M., Wang, Y., & Wu, L. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251362496 · Cited by 2
Guo, S., Wei, F., Chang, Y., Wu, S., Lou, Z., Ma, Y., Huang, Q., He, K., Fu, C., Cao, X., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07559-7 · Cited by 2
Chen, Y., Ding, L., Gu, Z., Tian, Z., Gao, T., Zhou, F., Zhang, S., & Tong, Z. (2025) · Aging and Disease · doi:10.14336/ad.2025.0873 · Cited by 2
Alzheimer's Disease Biomarker-Nigeria (ADIBIO-N): Cohort description and baseline data report
Ucheagwu, V. A., Morgan, D., Rose, S., Odilora, C., Okafor, C., & Giordani, B. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251394384 · Cited by 2
Neuropathology and Biomarker Correlates of Late Onset Alzheimer’s Disease in Aged Old World Monkeys
Zeiss, C. J., Duque, A., & Huttner, A. J. (2025) · Toxicologic Pathology · doi:10.1177/01926233251388069 · Cited by 2
Recognizing Structural and Social Determinants of Health in the Diagnosis and Care of Dementia
Stites, S. D., Midgett, S., Patel, N. S., Halberstadter, K., Schumann, R., Streitz, M. L., Shi, Y., Morris, J. C., Flatt, J. D., Glover, C. M., et al. (2025) · Dementia · doi:10.1177/14713012251397182 · Cited by 2
Association Between Plasma Phosphorylated Tau‐217 and Cognition in Parkinson's Disease
Kouchache, T., Chan, T., Sun, S., Liu, L., Delva, A., Gan‐Or, Z., Rosa‐Neto, P., Gagnon, J., Dagher, A., Postuma, R. B., et al. (2026) · Movement Disorders · doi:10.1002/mds.70400 · Cited by 2
Factors associated with discordant visual and quantitative amyloid PET results
Guevara, J. E., Matusz, E. F., Wang, W., DeSimone, J. C., Yawer, B. A., Fiala, J. A., Levy, S., Arias, F., Rayaprolu, S., Barker, W. W., et al. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70241 · Cited by 2
Jansen, R., Wagenhäuser, M. U., Kölsche, T., Papasimos, C., Benkert, P., Kühle, J., Pawlitzki, M., Masanneck, L., Schreiber, S., Caspers, J., et al. (2026) · JVS Vascular Science · doi:10.1016/j.jvssci.2026.100408 · Cited by 2
Limited Diagnostic Performance of Cerebrospinal Fluid Glial Fibrillary Acidic Protein in Dementia
Erickson, P., Skillbäck, T. B., Kern, S., Skoog, I. G., Jönsson, L., Andréasson, U., Blennow, K., Eriksdotter, M., & Zetterberg, H. (2026) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000550601 · Cited by 3
Self-citationBiomarcadores para diagnóstico e prognóstico de Alzheimer
Rodrigues, R. R., & Cardoso, A. M. (2026) · Revista Brasileira Militar de Ciências · doi:10.36414/rbmc.v12i26.211 · Cited by 2
Barrero, A. V., Martínez‐Dubarbie, F., Guerra, A., López‐García, S., Lage, C., Rivera‐Sánchez, M., Pozueta‐Cantudo, A., García‐Martínez, M., Corrales‐Pardo, A., Bravo, M. P. C., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02012-9 · Cited by 2
Self-citationEpigenetic aging and blood based neurodegeneration markers in LASI-DAD
Kim, J. K., Arpawong, T. E., Thyagarajan, B., Smith, J. A., Vivek, S., Ratliff, S. M., Dey, S., Lee, J., & Crimmins, E. M. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100595 · Cited by 2
Ahn, J., Yun, J., Weiner, M. W., Shin, D., Kang, H., Yim, S., Kim, S., Park, H., Jang, H. D., Chun, M. Y., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02077-6 · Cited by 2
Complex interplay of astrogliosis and pathology in preclinical Alzheimer's disease
Gogola, A., Minhas, D. S., Lopresti, B. J., Snitz, B. E., Reese, A. C., Matan, C., Wu, M., Zeng, X., Saeed, A., Reis, S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71520 · Cited by 2
Hanin, A., Quadrio, I., Beaudeux, J., & Lamari, F. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13896-w · Cited by 2
de Castro-Bono, A. V., Castro-Luna, G. M., & Guil‐Guerrero, J. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115042 · Cited by 3
Yao, M., Liu, A., Song, J., Xing, L., Zi, M., & Li, H. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.06.001 · Cited by 3
Chen, Y., Wang, Z., Chen, H., Li, H., Zhang, Z., Cui, H., Li, S., & Initiative, A. D. N. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13954-3 · Cited by 2
Zhang, J., Yang, N., Zou, P., & Zong, X. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03924-x · Cited by 2
Prominent Perspective on Existing Biological Hallmarks of Alzheimer’s Disease
Singh, N., Sharma, S., Ghosh, K. K., Gupta, B., & Kuča, K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266292514240404040341 · Cited by 2
Janadri, S., Shreelaxmi, D., Mudagal, M. P., Sharma, U., Vada, S., & Haribabu, T. (2025) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2025v17i1.6039 · Cited by 2
Zhao, K., Xie, H., Jacobs, T., Gaggi, N. L., Fortea, J., Carlisle, N. B., Fonzo, G. A., Pohl, K. M., Osorio, R. S., & Zhang, Y. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71757 · Cited by 2
Biomarker in der Diagnostik kognitiver Störungen – Empfehlungen der Swiss Memory Clinics
Popp, J., Georgescu, D., Bürge, M., Mundwiler, E., Bernasconi, L., & Felbecker, A. (2022) · Praxis · doi:10.1024/1661-8157/a003913 · Cited by 2
Rumo a uma nova era no diagnóstico e tratamento da doença de Alzheimer
Ferrari‐Souza, J. P., & Schilling, L. P. (2023) · PAJAR - Pan-American Journal of Aging Research · doi:10.15448/2357-9641.2023.1.44542 · Cited by 2
Norgren, J. (2023) · Open Archive (Karolinska Institutet) · Cited by 2
Atri, T. E., Denkinger, M. N., Liu, J., Singh, A., Surdyn, M., Brown, V. A., Martinez, G., Teran, M., Soza, V., Kuramoto, A., et al. (2026) · medRxiv · doi:10.64898/2026.08.13.26360406 · Cited by 2
Self-citationDi Caro, V., Cho, E., Thiel, J., Lizama, B. N., Koel-Simmelink, M. J. A., Pandey, K., Duong, D., Seyfried, N. T., Grundman, M., Teunissen, C. E., et al. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02025-4 · Cited by 1
“…astrogliosis, a hallmark of neuroinflammation, and given that plasma GFAP plasma levels correlations with Aβ pathology and disease progression [27] we sought to perform an exploratory analysis to seek to understand what proteins and biological pathways were associated with this change, by…”
Self-citationCurrent Treatment Approaches for Alzheimer’s Disease and Possible Drug Targets
Ranjan, A., Shukla, S., & Singh, S. (2024) · Current Drug Therapy · doi:10.2174/0115748855307998240529063710 · Cited by 1
Sun, F., Wang, Q., Zhao, L.-P., Jin, Q., Jin, S.-H., Xu, J., Yin, M.-J., Jin, C., & Wang, J. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251315388 · Cited by 1
Research Progress on Alzheimer's Disease Biomarkers Based on the ATX(N) Framework
Cao, H., Zhang, W., Lin, J., & Yu, E. (2025) · Discovery Medicine · doi:10.24976/discov.med.202537193.21 · Cited by 1
Blood biomarkers of Alzheimer’s disease: findings from proteomics
Wang, Y., Niu, X., Zhen, W., Zhang, B., Chen, L., Liu, Y., Sun, W., & Peng, D. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf039 · Cited by 1
Badmanaban, R., Menon, A., Kumar, A., V, B, R. L., Choudhury, A. A. K., Dhumal, J. S., Hazarika, N., Sarma, T., & Venkatesh, U. S. (2025) · Journal of Neonatal Surgery · doi:10.52783/jns.v14.2519 · Cited by 1
Schultz, B., Bobermin, L. D., Menezes, L., Gayger-Dias, V., Silva, V.-F. D., Taday, J., Alves, J., Tramontina, F. F., Zanotto, C., Dalmaz, C., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05046-6 · Cited by 1
Fluid and Imaging Markers of Glial Reactivity
Suárez‐Calvet, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_6 · Cited by 1
Impairment of astrocyte homeostasis and lysosomal function in Alzheimer’s disease pathogenesis
Collier, J. M., McFarland, M., Krishna, S., Kurella, P., Pinon, C. C., & Sun, D. (2025) · Aging and Disease · doi:10.14336/ad.2025.0694 · Cited by 1
Zhang, S., Wu, H., Ma, L., Li, R., Zhang, L., Liu, L., He, X., & Zhao, T. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1668512 · Cited by 1
Blood pressure dynamic instability and neurodegeneration in older adults
Lohman, T., Shenasa, F., Sible, I. J., Kapoor, A., Engstrom, A. C., Dutt, S., Head, E., Sordo, L., Alitin, J. P. M., Gaubert, A., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251386443 · Cited by 1
Yu, R., Suraev, A. S., Vidal, V., Kong, S. D., Zachariae, R. H., Piccio, L. M., Heneka, M. T., Naismith, S. L., & Michaelian, J. C. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03787-x · Cited by 1
Xu, Y., Qiao, M., Gunasekaran, T. I., Gu, Y., Reyes‐Dumeyer, D., Piriz, A. L., Sanchez, D. L., Soriano, B., Franco, Y., Coronado, Z. D., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70937 · Cited by 1
Sumadewi, K. T. (2025) · Health & Medical Sciences · doi:10.47134/phms.v3i1.519 · Cited by 1
Prueba neurocognitiva preoperatoria y su correlación con biomarcadores de daño cerebral
Antonello Penna, S., Egaña, J. I., Brisso, R., Ríos, D., Lobos, P., Caipo, L. I., & Gutiérrez, R. (2026) · Revista Chilena de Anestesia · doi:10.25237/revchilanestv55n1-10 · Cited by 1
Delaby, C., & Lehmann, S. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1731 · Cited by 1
Rao, A. R., Pradhan, R., Anwar, M., Gupta, A., Bhagwasia, M., Nichols, E., Gross, A. L., Thyagarajan, B., Hu, P., Crimmins, E. M., et al. (2026) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70336 · Cited by 1
Guo, Y., Huang, W., Xiong, X., Chen, H., Lv, C., Liu, T., Chen, F., & Initiative, A. D. N. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03883-0 · Cited by 1
From scaffold to effector: reframing GFAP in neurodegeneration
Lu, Y.-H., Zhu, X., Li, S., Zhang, F., Cai, C.-B., Tian, M., Zhu, Y., Zeng, L.-H., Tan, J., Changyin, Y., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.051 · Cited by 1
Chen, Y., Wang, Z., Chen, H., Cui, H., Li, S., & Initiative, A. D. N. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13726-z · Cited by 1
Patel, H., Choi, A., Weng, P. J., Karl, J. J., Joseph, S., Johnson, K. G., Berger, M., Whitson, H. E., Grewal, D. S., & Fekrat, S. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261423968 · Cited by 1
Wei, H., Zhang, C., Wen, P., Kong, M., & Ba, M. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70293 · Cited by 1
Li, S., Wei, S., Wang, L., Yu, T., Wang, H., Yang, S. B., Cao, W., & Zhang, X. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151452 · Cited by 1
Yoon, B. W., Lee, H.-J., Chae, H., Oh, E., Hong, Y. A., Jeong, J. H., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261427806 · Cited by 1
Wang, Y., Ma, X., Zou, Y., Wang, T., Chu, S., Mao, C., Yu, S., Gao, J., & Qiu, L. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1694 · Cited by 1
Association of plasma glial fibrillary acidic protein and APOE-ε4 with Alzheimer’s disease
Zhu, Y., Lan, G., Li, A., Zhang, L., Jiang, M., Yang, J., Zhu, J., He, Z., Xin, Z. H. O. U., Li, M., et al. (2026) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.03.009 · Cited by 1
From comorbidity to continuum: Alzheimer’s disease and epilepsy are connected-now what?
Alves, S. S., Manzine, P. R., dos Santos, F. M., Migliaccio, M. M., Alves, L. D. C., da Silva-Júnior, R. M. P., Becerra-Hernández, L. V., González-Acosta, C. A., Buriticá, E., Cominetti, M. R., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106682 · Cited by 1
Diabetes, hyperglycemia, and ATN blood biomarkers in Hispanic/Latino populations: SOL‐INCA study
González, K. A., Tarraf, W., Pa, J., Banks, S. J., Bangen, K. J., Galasko, D. R., Gallo, L. C., Stickel, A. M., Anita, N. Z., Márquez, F., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71223 · Cited by 1
Bonacci, M. C., Buonocore, J., Calomino, C., Bianco, M. G., Battocchio, M., Bontempi, P., Daducci, A., Cristiani, C. M., Quattrone, A., Caligiuri, M. E., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093934 · Cited by 1
Metabotropic glutamate receptor 5 is associated with plasma GFAP dependent on age
Hu, T., Wang, Y., Wang, J., Mao, X., Ren, S., He, K., Guan, Y., Huang, Q., Li, B., & Xie, F. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71473 · Cited by 1
Biomarkers in preclinical and early Alzheimer’s disease in China: a scoping review
Peng, G., Yang, Y., Wang, Y., Chandekar, S. A., & Yu, J. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100599 · Cited by 1
Ataov, G., Balaban, Ö. D., Cirakli, Z., & Yeşilkaya, Ü. H. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.05.015 · Cited by 1
Delaby, C., & Lehmann, S. (2026) · Laboratory Service · doi:10.17116/labs20261502137 · Cited by 1
Gaetani, L., Nardi, G., & Parnetti, L. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2700246 · Cited by 1
Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies
Yanagisawa, D., Ohgita, T., Kawashima, H., Yoshikawa, H., Saito, H., Tooyama, I., & Takata, K. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109084 · Cited by 1
Oliveira, M. S., Rodrigues, M. S., Amaral, L., Povala, G., da Rocha, A. S., Medeiros, M. S., Abbas, S., Ferrari‐Souza, J. P., Saha, P., Lussier, F. Z., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218336 · Cited by 1
Yoon, B., Lee, H.-J., Hong, Y. J., Park, K. H., Kim, S., Wang, M. J., Choi, S. H., Kang, S., Jeong, J. H., & Yang, D. W. (2026) · Journal of Clinical Neurology · doi:10.3988/jcn.2025.0659 · Cited by 1
Popp, J., Georgescu, D., Bürge, M., Mundwiler, E., Bernasconi, L., & Felbecker, A. (2022) · JMIG · doi:10.53738/revmed.2022.18.808.2400 · Cited by 1
Dem-Aging: autophagy-related pathologies and the “two faces of dementia”
Gammaldi, N., Doccini, S., Bernardi, S., Marchese, M., Cecchini, M. G., Ceravolo, R., Rapposelli, S., Ratto, G., Rocchiccioli, S., Pezzini, F., et al. (2023) · Neurogenetics · doi:10.1007/s10048-023-00739-3 · Cited by 1
Che, N., Ou, R., Li, C., Zhang, L., Wei, Q., Wang, S., Jiang, Q., Yang, T., Xiao, Y., Lin, J., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106732 · Cited by 1
He, M. T., Shin, Y. S., Kim, H. Y., & Cho, E. J. (2024) · Nutrition Research and Practice · doi:10.4162/nrp.2024.18.5.647 · Cited by 1
Biomarkers in dementia disorders – a narrative review
Hasselbalch, S. G. (2025) · Danish Medical Journal · doi:10.61409/a09240634 · Cited by 1
Ruiz-Ortiz, M., Lapeña-Motilva, J., de Bejar, V. G., Bartolomé, F. B., Alquézar, C., Martinez-Castillo, M., Wagner, S., del Ser, T., Nogales, M. A., Álvarez-Sesmero, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115122 · Cited by 1
Vrillon, A. (2022) · theses.fr (ABES) · doi:10.70675/58f64870z23eaz429bz9f78z6d92e769384b · Cited by 1
Leow, Y. J., Ismail, Z., Saffari, S. E., Sandhu, G. K., Tanoto, P., Lee, F. P. H. E., Ghildiyal, S., Liew, S. Y., Bhalla, G., Ying, S. X., et al. (2024) · medRxiv · doi:10.1101/2024.12.08.24318690 · Cited by 1
Riquelme-Contreras, P., Mery, I., Aguilera, S., Henriquez, F. A., Medel, V., Ferreira, P. C. L., Bellaver, B., Karikari, T. K., Pascoal, T. A., Thumala, D., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8621977/v1 · Cited by 1
Plaska, C. R., Jacobs, T., Bruno, D., Lee, S. H., Imbimbo, B. P., Osorio, R., Benedet, A. L., Ashton, N. J., Zetterberg, H., Pomara, N., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.30.702902 · Cited by 1
Self-citationGaubert, S. (2025) · theses.fr (ABES) · doi:10.70675/99646a75za67ez4777za088z782a66bc1c7e · Cited by 1
Poulakis, K., Ioannou, K., Bezgin, G., Chiotis, K., & Iturria‐Medina, Y. (2026) · medRxiv · doi:10.64898/2026.05.24.26353955 · Cited by 1
Oosthoek, M., Leistra, A., Hok‐A‐Hin, Y. S., Tanck, M. W. T., Okuda, T., Veld, L. I. ‘., Aladdin, A., van Bokhoven, P., Tijms, B. M., Jutten, R. J., et al. (2026) · medRxiv · doi:10.64898/2026.08.27.26361425 · Cited by 1
Self-citationCosta, A. P., Karim, H. T., Farinas, M. F., Geissinger, M. M., Zeng, X., Tudorascu, D. L., Butters, M. A., Karikari, T. K., & Andreescu, C. (2026) · medRxiv · doi:10.64898/2026.09.16.26363134 · Cited by 1
Serrano, S. (2006) · Cuadernos hispanoamericanos
Performance of plasma amyloid, tau, and astrocyte biomarkers to identify cerebral AD pathophysiologyPreprint
Ferreira, P. C. L., Tissot, C., Ferrari‐Souza, J. P., Brum, W. S., Bellaver, B., Leffa, D. T., Therriault, J., Benedet, A. L., Lussier, F. Z., Chamoun, M., et al. (2022) · medRxiv · doi:10.1101/2022.02.21.22271198
Self-citationMontoliu‐Gaya, L., Alcolea, D. A., Ashton, N. J., Pegueroles, J., Levin, J., Carmona‐Iragui, M., Lantero‐Rodriguez, J., Karikari, T. K., Barroeta, I., Kac, P. R., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4077901
Self-citationZhu, N., Santos‐Santos, M., Illán‐Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-958956/v1
Reducing unnecessary tau-PET scans in a memory clinic setting via blood-based biomarker screeningPreprint
Cullen, N. C., Janelidze, S., Stomrud, E., Palmqvist, S., Braum, W., Zetterberg, H., Frisoni, G. B., Ashton, N. J., Blennow, K., Mattsson, N., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1818516/v1
Self-citationAstrocytes in Huntington’s Disease Pathology: Implications for Biomarkers
You, H., & Pei, Z. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-32815-2_12
Kanuri, S. H., & Sirrkay, P. J. (2024) · Neurology Letters · doi:10.61186/nl.3.3.19
Cho, T., Kim, M., Kim, S. H., Lee, J. E., Kim, S. H., Kim, H. J., Hong, J.-E., Yeo, I., & Yang, H. (2024) · Cells Tissues Organs · doi:10.1159/000540976
Posttraumatic Stress Disorder (PTSD) and Glial Suppression
Kritikos, M., & Clouston, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_144-1
Bogner, C. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-10978
Stem Cell Based Therapies for Neurological Disorders
Aziz, A., Majeed, S., & Gul, S. (2025) · Penerbit BRIN eBooks · doi:10.55981/brin.1128.c1301
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.